Indications and Usage

Question 1

Indication for Melanoma

Answer 1

1. BRAF V600 wild-type unresectable or metastatic melanoma, as a single agent.
2. BRAF V600 mutation-positive unresectable or metastatic melanoma, as a single agent. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Question 2

Indication for Melanoma in combination

Answer 2

Unresectable or metastatic melanoma, in combination with ipilimumab. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Question 3

Indication for Lung

Answer 3

Metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

Question 4

Indication for Renal Cell

Answer 4

Advanced renal cell carcinoma who have received prior anti-angiogenic therapy.

Question 5

Indication for Classical Hodgkin Lymphoma

Answer 5

Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.